On March 1, the U.S. Food and Drug Administration (FDA) granted accelerated approval to melphalan flufenamide (melflufen) in combination with dexamethasone for the treatment of relapsed/refractory (RR) multiple myeloma (MM). Melflufen, sold commercially as PEPAXTO, is the first peptide-drug conjugate approved for the treatment of MM. The newly approved therapeutic combination has been designated for … Continue reading Melflufen Combination Approved for Heavily Pretreated Multiple Myeloma